Pfizer Inc. (NYSE:PFE) Receives Average Rating of “Moderate Buy” from Analysts

Pfizer Inc. (NYSE:PFEGet Rating) has received a consensus rating of “Moderate Buy” from the twenty-one brokerages that are covering the firm, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold recommendation, eight have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $57.26.

A number of research firms recently weighed in on PFE. SVB Leerink assumed coverage on shares of Pfizer in a research note on Monday, May 23rd. They set a “market perform” rating and a $55.00 target price on the stock. Wells Fargo & Company cut their price target on shares of Pfizer from $60.00 to $55.00 in a report on Wednesday, May 4th. JPMorgan Chase & Co. set a $57.00 price target on shares of Pfizer in a report on Tuesday, May 3rd. Barclays set a $52.00 price target on shares of Pfizer in a report on Tuesday, May 17th. Finally, The Goldman Sachs Group set a $51.00 target price on shares of Pfizer in a research report on Wednesday, May 25th.

In related news, SVP Jennifer B. Damico sold 4,000 shares of the business’s stock in a transaction on Monday, May 16th. The stock was sold at an average price of $50.50, for a total transaction of $202,000.00. Following the sale, the senior vice president now owns 15,064 shares in the company, valued at approximately $760,732. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Jennifer B. Damico sold 4,218 shares of the business’s stock in a transaction dated Tuesday, June 7th. The shares were sold at an average price of $53.96, for a total value of $227,603.28. Following the completion of the transaction, the senior vice president now directly owns 10,846 shares in the company, valued at $585,250.16. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 41,126 shares of company stock valued at $2,075,003. 0.05% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently modified their holdings of the business. Worth Asset Management LLC purchased a new stake in Pfizer in the first quarter worth about $29,000. Econ Financial Services Corp purchased a new position in shares of Pfizer during the fourth quarter valued at approximately $31,000. PYA Waltman Capital LLC purchased a new position in shares of Pfizer during the fourth quarter valued at approximately $31,000. Rinkey Investments purchased a new position in shares of Pfizer during the fourth quarter valued at approximately $32,000. Finally, Stuart Chaussee & Associates Inc. lifted its holdings in shares of Pfizer by 108.3% during the first quarter. Stuart Chaussee & Associates Inc. now owns 625 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 325 shares during the last quarter. Institutional investors and hedge funds own 66.50% of the company’s stock.

NYSE PFE opened at $49.07 on Thursday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.39 and a quick ratio of 1.13. The stock has a market capitalization of $275.33 billion, a PE ratio of 11.25, a PEG ratio of 0.56 and a beta of 0.76. Pfizer has a 1 year low of $38.82 and a 1 year high of $61.71. The business’s 50-day moving average is $50.57 and its 200 day moving average is $52.22.

Pfizer (NYSE:PFEGet Rating) last released its earnings results on Tuesday, May 3rd. The biopharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.66 by ($0.04). Pfizer had a net margin of 26.97% and a return on equity of 38.29%. The business had revenue of $25.66 billion for the quarter, compared to analysts’ expectations of $24.73 billion. During the same quarter in the previous year, the business posted $0.93 earnings per share. Pfizer’s revenue for the quarter was up 76.8% on a year-over-year basis. As a group, equities research analysts anticipate that Pfizer will post 6.61 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which was paid on Friday, June 10th. Shareholders of record on Friday, May 13th were given a $0.40 dividend. This represents a $1.60 annualized dividend and a yield of 3.26%. The ex-dividend date was Thursday, May 12th. Pfizer’s dividend payout ratio (DPR) is presently 36.70%.

Pfizer Company Profile (Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Recommended Stories

Analyst Recommendations for Pfizer (NYSE:PFE)

Want More Great Investing Ideas?

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.